New cell therapy targets EBV-Linked cancers in early trial

NCT ID NCT07450391

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study is testing an experimental cell therapy called EBV-AST for people with Epstein-Barr virus (EBV)-related lymphoproliferative disorders, including certain blood cancers and post-transplant complications. About 18 adults will receive up to 3 infusions of the treatment to check safety and find the best dose. The goal is to see if the therapy can shrink tumors and control the disease, but it is not expected to be a cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

angioimmunoblastic T-cell lymphoma Burkitt lymphoma Epstein-Barr virus-associated lymphoproliferative disorder Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly Epstein-Barr virus-related tumor extranodal nasal NK/T cell lymphoma Hodgkins lymphoma hydroa vacciniforme-like lymphoma post-transplant lymphoproliferative disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chinese PLA General Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100853, China

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••